Literature DB >> 18799318

Preoperative staging of mesothelioma by 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography fused imaging and mediastinoscopy compared to pathological findings after extrapleural pneumonectomy.

Jens Benn Sørensen1, Jesper Ravn, Annika Loft, Jørn Brenøe, Anne Kiil Berthelsen.   

Abstract

OBJECTIVES: Extrapleural pneumonectomy (EPP) in MPM may be confined with both morbidity and mortality and careful preoperative staging identifying resectable patients is important. Staging is difficult and the accuracy of preoperative CT scan, 18F-FDG PET/CT scan (PET/CT), and mediastinoscopy is unclear. The objectives were to compare these staging techniques to each other and to surgical-pathological findings.
METHODS: Patients had epithelial subtype MPM, age <or=70 years, and lung function test allowing pneumonectomy. Preoperative staging after 3-6 courses of induction chemotherapy included conventional CT scan, PET/CT, and mediastinoscopy. Surgical-pathological findings were compared to preoperative findings.
RESULTS: Forty-two consecutive patients were without T4 or M on CT scan. PET/CT showed inoperability in 12 patients (29%) due to T4 (7 patients) and M1 (7 patients). Among 30 patients with subsequent mediastinoscopy, including 10 with N2/N3 on PET/CT, N2 were histologically verified in 6 (20%). Among 24 resected patients, T4 occurred in 2 patients (8%), and N2 in 4 (17%), all being PET/CT negative. PET/CT accuracy of T4 and N2/N3 compared to combined histological results of mediastinoscopy and EPP showed sensitivity, specificity, positive predictive value, negative predictive value, and positive and negative likelihood ratios of 78% and 50%, 100% and 75%, 100% and 50%, 94% and 75%, not applicable and 5.0, and 0.22 and 0.67, respectively.
CONCLUSIONS: Non-curative surgery is avoided in 29% out of 42 MPM patients by preoperative PET/CT and in further 14% by mediastinoscopy. Even though both procedures are valuable, there are false negative findings with both, urging for even more accurate staging procedures.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18799318     DOI: 10.1016/j.ejcts.2008.07.050

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  10 in total

1.  Current issues in malignant pleural mesothelioma evaluation and management.

Authors:  Jing Ai; James P Stevenson
Journal:  Oncologist       Date:  2014-07-24

Review 2.  Malignant pleural mesothelioma: predictors and staging.

Authors:  William G Richards
Journal:  Ann Transl Med       Date:  2017-06

Review 3.  Guidelines for the diagnosis and treatment of malignant pleural mesothelioma.

Authors:  Nico van Zandwijk; Christopher Clarke; Douglas Henderson; A William Musk; Kwun Fong; Anna Nowak; Robert Loneragan; Brian McCaughan; Michael Boyer; Malcolm Feigen; David Currow; Penelope Schofield; Beth Ivimey Nick Pavlakis; Jocelyn McLean; Henry Marshall; Steven Leong; Victoria Keena; Andrew Penman
Journal:  J Thorac Dis       Date:  2013-12       Impact factor: 2.895

Review 4.  Current evidence base of FDG-PET/CT imaging in the clinical management of malignant pleural mesothelioma: emerging significance of image segmentation and global disease assessment.

Authors:  Sandip Basu; Babak Saboury; Drew A Torigian; Abass Alavi
Journal:  Mol Imaging Biol       Date:  2011-10       Impact factor: 3.488

Review 5.  Role of thoracoscopy, mediastinoscopy and laparoscopy in the diagnosis and staging of malignant pleural mesothelioma.

Authors:  Ori Wald; Shawn S Groth; Bryan M Burt; David J Sugarbaker
Journal:  J Vis Surg       Date:  2016-08-02

6.  Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline.

Authors:  Hedy L Kindler; Nofisat Ismaila; Samuel G Armato; Raphael Bueno; Mary Hesdorffer; Thierry Jahan; Clyde Michael Jones; Markku Miettinen; Harvey Pass; Andreas Rimner; Valerie Rusch; Daniel Sterman; Anish Thomas; Raffit Hassan
Journal:  J Clin Oncol       Date:  2018-01-18       Impact factor: 44.544

7.  Identification of a seven glycopeptide signature for malignant pleural mesothelioma in human serum by selected reaction monitoring.

Authors:  Ferdinando Cerciello; Meena Choi; Annalisa Nicastri; Damaris Bausch-Fluck; Annemarie Ziegler; Olga Vitek; Emanuela Felley-Bosco; Rolf Stahel; Ruedi Aebersold; Bernd Wollscheid
Journal:  Clin Proteomics       Date:  2013-11-08       Impact factor: 3.988

8.  Malignant paratesticular mesothelioma.

Authors:  Leonardo Gomes da Fonseca; Daniel Fernandes Marques; Tiago Kenji Takahashi; Fernando Nalesso Aguiar; Juliana Naves Ravanini; Daniel Fernandes Saragiotto
Journal:  Autops Case Rep       Date:  2014-03-31

9.  An Autopsied Case of Malignant Sarcomatoid Pleural Mesothelioma in Which Chest Pain Developed Several Months Earlier without Abnormality on Imaging.

Authors:  Daizo Yaguchi; Motoshi Ichikawa; Noriko Inoue; Daisuke Kobayashi; Akinobu Matsuura; Masato Shizu; Naoyuki Imai; Kazuko Watanabe
Journal:  Case Rep Oncol       Date:  2015-10-21

Review 10.  Clinical staging of malignant pleural mesothelioma: current perspectives.

Authors:  Maria Bonomi; Costantino De Filippis; Egesta Lopci; Letizia Gianoncelli; Giovanna Rizzardi; Eleonora Cerchiaro; Luigi Bortolotti; Alessandro Zanello; Giovanni Luca Ceresoli
Journal:  Lung Cancer (Auckl)       Date:  2017-08-18
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.